Evercore ISI initiates Lycia stock with outperform rating
Evercore ISI initiated coverage on Lycia Therapeutics (NASDAQ:LYCA) with an outperform rating and a $43 price target, citing its LYTACs technology. The company's lead program targets IgE, with clinical trials for food allergies and Graves disease. Lycia raised $318 million in its IPO, priced at $18 per share. Jefferies and TD Cowen also initiated coverage with buy ratings and price targets of $50 and unspecified, respectively.